newsfilter
← Latest News
GlobeNewswire·

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

U.S. Food and Drug Administration (FDA) review of oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission remains on track, with a Prescription Drug User Fee Act (PDUFA) target action date of June 29,